天域生物
(603717)
| 流通市值：14.65亿 | | | 总市值：14.65亿 |
| 流通股本：2.90亿 | | | 总股本：2.90亿 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 524,313,367.84 | 350,661,138.6 | 153,901,746.67 | 725,588,873.17 |
| 营业收入 | 524,313,367.84 | 350,661,138.6 | 153,901,746.67 | 725,588,873.17 |
| 二、营业总成本 | 603,229,264.47 | 398,188,983.82 | 173,927,518.76 | 835,851,001.34 |
| 营业成本 | 531,617,192.14 | 354,047,395.92 | 143,861,684.08 | 726,495,343.41 |
| 税金及附加 | 1,117,279.31 | 584,255.99 | 268,530.24 | 2,289,741.62 |
| 销售费用 | 4,115,659.48 | 2,129,339.12 | 939,457.42 | 4,375,633.04 |
| 管理费用 | 47,814,927.39 | 34,311,490.95 | 15,318,692.95 | 79,704,349.84 |
| 研发费用 | 6,655,949.32 | 3,892,831.35 | 1,975,936.63 | 13,921,859.21 |
| 财务费用 | 11,908,256.83 | 3,223,670.49 | 11,563,217.44 | 9,064,074.22 |
| 其中:利息费用 | 33,489,842.46 | 24,873,223.75 | 12,675,916.94 | 53,336,334.08 |
| 其中:利息收入 | 22,618,593.13 | 21,966,722.05 | 1,483,085.19 | 46,234,484.51 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 3,177,148.1 | -3,184,605.53 | 3,359,482.98 | 8,633,602.76 |
| 加:投资收益 | 29,447,090.15 | 14,391,021.64 | 16,854,018.71 | -4,114,472.65 |
| 资产处置收益 | -2,805,739.4 | -56,646 | -7,201.17 | 25,973,538.27 |
| 资产减值损失(新) | -24,016,701.86 | -11,370,262.87 | -12,308,147.82 | -22,928,085.66 |
| 信用减值损失(新) | -8,445,781.8 | -3,928,469.02 | 5,124,689.87 | -2,403,113.01 |
| 其他收益 | 767,328.11 | 582,707.03 | 363,324.36 | 3,195,085.31 |
| 四、营业利润 | -80,792,553.33 | -51,094,099.97 | -6,639,605.16 | -101,905,573.15 |
| 加:营业外收入 | 4,734,615.79 | 3,948,652.01 | 435,231.18 | 11,146,501.83 |
| 减:营业外支出 | 3,511,246.24 | 1,900,066.34 | 621,126.96 | 5,469,570.86 |
| 五、利润总额 | -79,569,183.78 | -49,045,514.3 | -6,825,500.94 | -96,228,642.18 |
| 减:所得税费用 | -113,122.84 | 2,564,497.33 | -196,979.86 | 5,786,963.97 |
| 六、净利润 | -79,456,060.94 | -51,610,011.63 | -6,628,521.08 | -102,015,606.15 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -79,456,060.94 | -51,610,011.63 | -6,628,521.08 | -102,015,606.15 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -88,839,960.51 | -54,376,311.09 | -10,518,672.2 | -106,903,872.77 |
| 少数股东损益 | 9,383,899.57 | 2,766,299.46 | 3,890,151.12 | 4,888,266.62 |
| 扣除非经常损益后的净利润 | -108,086,619.4 | -63,780,002.8 | -21,170,027.6 | -138,808,459.34 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -0.31 | -0.19 | -0.04 | -0.37 |
| (二)稀释每股收益 | -0.31 | -0.19 | -0.04 | -0.37 |
| 九、综合收益总额 | -79,456,060.94 | -51,610,011.63 | -6,628,521.08 | -102,015,606.15 |
| 归属于母公司股东的综合收益总额 | -88,839,960.51 | -54,376,311.09 | -10,518,672.2 | -106,903,872.77 |
| 归属于少数股东的综合收益总额 | 9,383,899.57 | 2,766,299.46 | 3,890,151.12 | 4,888,266.62 |
| 公告日期 | 2026-10-31 | 2026-08-29 | 2026-04-30 | 2026-04-30 |
| 审计意见(境内) | | | | 标准无保留意见 |